BridgeBio Pharma, Inc. (BBIO) Profit Margins
Over the twelve months to 2026-06-30, BridgeBio Pharma, Inc. (BBIO) had operating margin -69.8%, net margin -97.0%, free cash flow margin -61.1%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
BBIOBridgeBio Pharma, Inc.Follow BBIO — free
—
Price chart with a free account
- Market cap
- 13.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | 96.1% | — | 73.7% | 98.3% | 95.8% | — | |
| Operating margin | -656.4% | -5752.0% | -827.1% | -659.6% | -6528.8% | -267.2% | -104.2% | -69.8% | |
| Net margin | -642.5% | -5439.7% | -806.9% | -624.2% | -6913.9% | -241.4% | -144.4% | -97.0% | |
| FCF margin | -631.7% | -4936.7% | -733.2% | -546.5% | -5686.6% | -235.1% | -89.0% | -61.1% |
USD billions · SEC XBRL
BridgeBio Pharma, Inc. — questions
- What is BridgeBio Pharma, Inc.'s operating margin?
- -69.8% over the twelve months to 2026-06-30.
- What is BridgeBio Pharma, Inc.'s net profit margin?
- -97.0% over the twelve months to 2026-06-30.
Every figure on this page comes from BridgeBio Pharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.